Yoon Young Cho1,2, Hye Jeong Kim3, Hye Won Jang4, Tae Hyuk Kim5, Chang-Seok Ki6, Sun Wook Kim5, Jae Hoon Chung7. 1. Division of Endocrinology and Metabolism, Department of Medicine, Gyeongsang National University School of Medicine, Jinju, Korea. 2. Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. 4. Department of Medical Education, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 6. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 7. Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. thyroid@skku.edu.
Abstract
PURPOSE: Levothyroxine supplementation is insufficient for the management of one tenth of patients with hypothyroidism. Iodothyronine deiodinases have been suggested to play a role in residual hypothyroid symptoms of these patients by controlling local thyroid hormone homeostasis. Previous research has suggested a relationship between commonly inherited variations in type 2 iodothyronine deiodinase and impaired well-being. We evaluated the prevalence of iodothyronine deiodinase genotypes and their association with psychological well-being in the Korean hypothyroid population. METHODS: A prospective observational study. We enrolled 196 hypothyroid subjects (136 chronic autoimmune thyroiditis and 60 thyroid cancer) and assessed baseline well-being using six validated questionnaires. Genotyping was conducted for 19 single nucleotide polymorphisms in type 1, 2, and 3 iodothyronine deiodinase using Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all patients. RESULTS: Frequencies of iodothyronine deiodinase genotypes and well-being scores were not different in hypothyroid subjects according to their disease types. Minor genotypes of a few iodothyronine deiodinase 1 variants (rs11206244, rs2294512, and rs4926616) were associated with reduced psychological well-being. However, iodothyronine deiodinase 2 and 3 variants had no effect on baseline well-being. CONCLUSION: Minor variations in iodothyronine deiodinase 1 were associated with decreased well-being in the Korean hypothyroid population, whereas iodothyronine deiodinase 2 and 3 were not. Due to controversial results among different ethnicities, further studies to clarify the effects of iodothyronine deiodinase polymorphisms on psychological well-being are warranted in hypothyroid individuals.
PURPOSE:Levothyroxine supplementation is insufficient for the management of one tenth of patients with hypothyroidism. Iodothyronine deiodinases have been suggested to play a role in residual hypothyroid symptoms of these patients by controlling local thyroid hormone homeostasis. Previous research has suggested a relationship between commonly inherited variations in type 2 iodothyronine deiodinase and impaired well-being. We evaluated the prevalence of iodothyronine deiodinase genotypes and their association with psychological well-being in the Korean hypothyroid population. METHODS: A prospective observational study. We enrolled 196 hypothyroid subjects (136 chronic autoimmune thyroiditis and 60 thyroid cancer) and assessed baseline well-being using six validated questionnaires. Genotyping was conducted for 19 single nucleotide polymorphisms in type 1, 2, and 3 iodothyronine deiodinase using Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all patients. RESULTS: Frequencies of iodothyronine deiodinase genotypes and well-being scores were not different in hypothyroid subjects according to their disease types. Minor genotypes of a few iodothyronine deiodinase 1 variants (rs11206244, rs2294512, and rs4926616) were associated with reduced psychological well-being. However, iodothyronine deiodinase 2 and 3 variants had no effect on baseline well-being. CONCLUSION: Minor variations in iodothyronine deiodinase 1 were associated with decreased well-being in the Korean hypothyroid population, whereas iodothyronine deiodinase 2 and 3 were not. Due to controversial results among different ethnicities, further studies to clarify the effects of iodothyronine deiodinase polymorphisms on psychological well-being are warranted in hypothyroid individuals.
Authors: Vijay Panicker; Christie Cluett; Beverley Shields; Anna Murray; Kirstie S Parnell; John R B Perry; Michael N Weedon; Andrew Singleton; Dena Hernandez; Jonathan Evans; Claire Durant; Luigi Ferrucci; David Melzer; Ponnusamy Saravanan; Theo J Visser; Graziano Ceresini; Andrew T Hattersley; Bijay Vaidya; Colin M Dayan; Timothy M Frayling Journal: J Clin Endocrinol Metab Date: 2008-05-20 Impact factor: 5.958
Authors: Elizabeth A McAninch; Sungro Jo; Nailliw Z Preite; Erzsébet Farkas; Petra Mohácsik; Csaba Fekete; Péter Egri; Balázs Gereben; Yan Li; Youping Deng; Mary-Elizabeth Patti; Chantal Zevenbergen; Robin P Peeters; Deborah C Mash; Antonio C Bianco Journal: J Clin Endocrinol Metab Date: 2015-01-08 Impact factor: 5.958
Authors: Robert A Philibert; Steven R H Beach; Tracy D Gunter; Alexandre A Todorov; Gene H Brody; Meeshanthini Vijayendran; Lilly Elliott; Nancy Hollenbeck; Daniel Russell; Carolyn Cutrona Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-05-11 Impact factor: 3.568
Authors: Young Ho Yun; Xin Shelley Wang; Jung Suk Lee; Ju Won Roh; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Tito R Mendoza; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2005-02 Impact factor: 3.612
Authors: Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871